Sign in

Emil Lou, MD, PhD, FACP, FASCO

@cancerassassin1.bsky.social
2.3K followers 646 following 273 posts

@TIME 100 Health 2026. Physician-Scientist/Clinical Cancer Biologist/GI Medical Oncologist. In lab: Cancer Cell Biology, uncovering how #TunnelingNanotubes drive ChemoResistance. time.com/collections/time100-health…

PostsRepliesMedia
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Knowable Magazine @knowablemag.bsky.social · 05/09/2026
🎗️ Thinking of others enhances your well-being, while selfishness just adds to stress, studies show. ✍️ @kendallsciwrite.bsky.social: knowmag.org/4wYLHOI
knowablemagazine.org
Do yourself a favor
Thinking of others enhances your well-being, while selfishness just adds to stress, studies show
043
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Robert S Miller MD @rsm2800.bsky.social · 26/08/2026
We knew it was coming after the presentation at #ASCO26 but this is still a historic day www.fda.gov/drugs/resour...
fda.gov
FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma
The FDA approved daraxonrasib, an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma.
031
Reposted by Emil Lou, MD, PhD, FACP, FASCO
The New Yorker @newyorker.com · 26/08/2026
From the daily newsletter: the musician, who died today at the age of eighty, leaves behind a legacy of enormous warmth and tenderness. www.newyorker.com/newsletter/t...
newyorker.com
What Dolly Parton Built
From the daily newsletter: the musician, who died today at the age of eighty, leaves behind a legacy of enormous warmth and tenderness.
111514
Reposted by Emil Lou, MD, PhD, FACP, FASCO
CNN @cnn.com · 26/08/2026
Legendary singer-songwriter Dolly Parton died after facing a "brief battle" with cancer, her publicist said in a statement. cnn.it/4wKlp2x
711940
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 30/07/2026
Inflammation Keeps Us Alive. It's Also Making Us Sick. www.nytimes.com/interactive/...
nytimes.com
Inflammation Keeps Us Alive. It's Also Making Us Sick.
The discovery that chronic inflammation is a cause of myriad illnesses could be this century's biggest medical breakthrough.
000
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 18/06/2026
Beyond the Data: How Physicians Talk to Patients About Uncertainty: #podcast episode from @nanets.bsky.social Available here: podcasts.apple.com/us/podcast/b...
140
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Ajay Prakash, MD, PhD @cancertrials.bsky.social · 10/06/2026
@cancerassassin1.bsky.social and I break down the implications of the recent RASolute 302 phase 3 clinical trial, and the impact it will have on the field: ascopost.com/issues/june-... We have more publications coming on the future of KRAS! #ASCOPost #ASCO2026 #daraxonrasib #OncSky
ascopost.com
Daraxonrasib in <em>KRAS</em>-Mutant Pancreatic Cancer: A First Step in Shifting the Paradigm of Treatment
Wolpin and colleagues have demonstrated in the global randomized Phase III RASolute 302 trial that daraxonrasib, an oral RAS(ON) inhibitor, nearly doubles median overall survival in previously treated...
131
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 10/06/2026
My colleague GI Oncologist Dr. Ajay Prakash @cancertrials.bsky.social #UMN breaks it down for The @ascopost.bsky.social @ascocancer.bsky.social Published June 10, 2026: Daraxonrasib in KRAS-Mutant Pancreatic Cancer: A First Step in Shifting the Paradigm of Treatment ascopost.com/issues/june-...
011
Reposted by Emil Lou, MD, PhD, FACP, FASCO
American Society of Clinical Oncology @ascocancer.bsky.social · 31/05/2026
Major news from #ASCO26: A multi-selective RAS(ON) inhibitor nearly doubles survival time in people with metastatic pancreatic cancer. “This is absolutely practice-changing” says Dr. Shruti Patel in this Science in Seconds. #pancan Read the abstract: bit.ly/4dChEWM
163
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 31/05/2026
Research co-authored by MSK gastrointestinal medical oncologist Dr. Eileen O’Reilly will be presented during the plenary session at #ASCO26.
132
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Ajay Prakash, MD, PhD @cancertrials.bsky.social · 31/05/2026
Great discussion of current ASCO controversies by @cancerassassin1.bsky.social Go watch the full episode when posted: youtube.com/@onlyoncs?si...
youtube.com
Only Oncologists In the Building
We're not solving murders, but we are tackling medical misconceptions! Join three physicians in "Only Oncologists in the Building" for straightforward healthcare news. Hit subscribe for your dose of ...
011
Reposted by Emil Lou, MD, PhD, FACP, FASCO
American Cancer Society @americancancersoc.bsky.social · 30/05/2026
During this morning's Opening Session at #ASCO26, we were proud to see three past and present ACS grantees included in the newest class of Fellows of the @ascocancer.bsky.social: - Dr. Chloe E. Atreya - Dr. Areej El-Jawahri - @cancerassassin1.bsky.social Congrats to all on earning your #FASCO!
221
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Ajay Prakash, MD, PhD @cancertrials.bsky.social · 30/05/2026
Lots of exciting advances coming through at @ascocancer.bsky.social 2026 A great meeting with @cancerassassin1.bsky.social regarding KLEOS, the new CCA trial platform
011
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 29/05/2026
With decades of research culminating in an explosive arrival this spring of clinical trial data for KRAS inhibitors, PBS NewsHour breaks it down in time for #ASCO26, thanks @pbsnews.org team for the opportunity. www.pbs.org/newshour/hea...
pbs.org
Pancreatic cancer is deadly and difficult to treat. A new pill could change that
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
040
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Trevor Graham @trevorgraham.bsky.social · 13/04/2026
Cases of bowel cancer in young adults are increasing at an alarming rate: there are too many stories like Bradley's, a young man who died from bowel cancer in his early twenties. @icr.ac.uk are fundraising so we can lead more research to prevent and better treat bowel cancer at all ages.
052
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Trevor Graham @trevorgraham.bsky.social · 12/11/2024
I've started a list of people working on #cancer #evolution. Many more to be added, so do let me know if that is you. Also if you would like to be removed. go.bsky.app/QuAF4Mo
399130
Reposted by Emil Lou, MD, PhD, FACP, FASCO
OHSU Knight Cancer Institute @ohsuknight.bsky.social · 20/04/2026
“These tools let us see critical cancer‑related processes happening live, at the very small scale where key decisions are made inside cells.” - Dr. Cathy Galbraith on new imaging tools that help cancer researchers see inside living cells:
news.ohsu.edu
New imaging tools help cancer researchers see inside living cells
OHSU scientist helps develop imaging strategy that unlocks next-generation dyes to study how cancer cells grow, move, change in real time.
042
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 19/04/2026
Very happy to be here at #AACR26 with our outstanding @theaacr.bsky.social AACR Scientist↔️Survivor Program partner advocates. 47 patient advocates on site from around the world, selected from over 400 (!) applications.
031
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 19/04/2026
The American Cancer Society here in full force at #AACR26! I am so grateful for support including research funding for my lab. Follow the ACS on #Bluesky @americancancersoc.bsky.social
030
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Yale Cancer Center @yalecancer.bsky.social · 18/04/2026
“The burden of #cancer is not equally shared,” Dr. Pat LoRusso spotlights hybrid decentralization, a successful model for improved #clinicaltrials access. #AACR26. By blending expertise with community access, the program accelerates enrollment & brings trials closer to pts. @oncoalert.bsky.social
021
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 18/04/2026
Today is #SupermanDay, and the first full day of #AACR26. You don’t have to leap tall buildings in a single bound to make a difference. Supporting or otherwise contributing to research 🔬 in cancer biology and in #oncology #clinicaltrials makes a difference. Up up and away @theaacr.bsky.social !
030
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 15/04/2026
Ready for #AACR26, the Annual Meeting of @theaacr.bsky.social that starts later this week in San Diego. An especially exciting year to talk #cancerresearch, across the spectrum from lab (mitochondrial biology, cell communication) to clinic (targeting RAS RAS RAS, immunotherapy...and more).
181
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 07/04/2026
My commentary in @medscape.com on a range of topics covered at #GI26: ASCO GI: Practice-Changing Signals Across Pancreatic, Gastric, and Colorectal Cancers www.medscape.com/viewarticle/...
medscape.com
ASCO GI: Updates in Pancreatic, Gastric, CRC
Dr Emil Lou highlights practice-changing updates from ASCO GI, including new immunotherapy, targeted therapy, and circulating tumor DNA advances across gastrointestinal cancers.
010
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Richard Sever @richardsever.bsky.social · 04/04/2026
CRUK goes green [OA] news.cancerresearchuk.org/2026/04/01/w...
news.cancerresearchuk.org
Why we won’t be funding open access publishing any more - Cancer Research UK - Cancer News
The open access movement was bold and promising, but ultimately disappointing. Now is the time to stop and call for a new way to make publishing work…
33727
Reposted by Emil Lou, MD, PhD, FACP, FASCO
The New Yorker @newyorker.com · 24/02/2026
In terms of extending life, getting an H.P.V. vaccine is as important for a woman as quitting smoking, according to an emeritus professor of epithelial biology at the University of Cambridge. newyorkermag.visitlink.me/Q3Ef0J
newyorkermag.visitlink.me
One Vaccine-Schedule Change That Actually Makes Sense
A Vaccine-Schedule Change Just Made H.P.V. Easier to Prevent
07427
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 21/02/2026
Well worth a read: August 2024 article in @fastcompany.com by Nathan Phillips about grasping his diagnosis of young-adult cancer: Creative directing my cancer www.fastcompany.com/91180630/cre...
fastcompany.com
Creative directing my cancer
Selling myself on my stage 4 cancer diagnosis was the hardest marketing brief I'd ever gotten. Nailing it showed me how to live.
000
Reposted by Emil Lou, MD, PhD, FACP, FASCO
The Athletic | Football @theathleticfc.bsky.social · 20/02/2026
Werder Bremen will not fulfil their proposed summer tour of the U.S., citing recent incidents in Minneapolis, Minnesota as “not fitting the values” of the club. More from @colinmillar.bsky.social and @sebsb.bsky.social www.nytimes.com/athletic/705...
850095
Reposted by Emil Lou, MD, PhD, FACP, FASCO
CU Anschutz Cancer Center @cucancercenter.bsky.social · 12/02/2026
Back in November 2024, actor James Van Der Beek announced that he had been diagnosed with colorectal cancer at age 47, highlighting that it’s not just a disease that older people need to be concerned about. Christopher Lieu, MD, tells us more about colorectal cancer ⬇️ bit.ly/3Z3DjQt
news.cuanschutz.edu
'You're Never Too Young': CU Anschutz Cancer Center Expert on James Van Der Beek’s Colorectal Cancer
Actor James Van Der Beek has died, according to news media accounts February 11, 2026. This article was first published November 5, 2024, after he disclosed his colorectal cancer diagnosis.
032
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 11/02/2026
Honored & humbled by this beyond measure. The real credit and spotlight goes to my brave patient Emma and all of the patients and caregivers who fearlessly volunteer for #clinicaltrials seeking hope while helping the world find better cancer treatments. We need more Emmas. time.com/collections/...
210
Reposted by Emil Lou, MD, PhD, FACP, FASCO
CNN @cnn.com · 11/02/2026
James Van Der Beek, who rose to fame playing Dawson Leery on the 1990s-era hit teen drama “Dawson’s Creek,” has died. He was 48. cnn.it/3ZwnNfk
310225
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 06/02/2026
Anytime we can join @chadinabhan.bsky.social for a special #HealthcareUnfiltered episode, we're all in. I was pleased to join @shaalanbeg.bsky.social & @shrutipatelmd.bsky.social to highlight data from @ascocancer.bsky.social #GI26 ⁦ Listen or watch the #podcast: podcasts.apple.com/us/podcast/e...
podcasts.apple.com
Episode 265: ASCO GI Updates: Special Episode
Podcast Episode · Healthcare Unfiltered · 02/05/2026 · 58m
031
Reposted by Emil Lou, MD, PhD, FACP, FASCO
CNN @cnn.com · 05/02/2026
Catherine, Princess of Wales has spoken of her experience with cancer, in a deeply personal video message released Wednesday to mark World Cancer Day. cnn.it/3ZiKHXi
79010
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 04/02/2026
Today is World Cancer Day, a global awareness day organized by the Union of International Cancer Control (UICC) every February 4th. An emphasis from the UICC is that ~40% of cancers are driven or associated with preventable risk factors. More information here: www.nccn.org/home/world-c...
021
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 04/02/2026
Happy National Women Physicians Day! Today, we celebrate the incredible contributions of women in medicine, and we especially remember a true pioneer: Dr. Elizabeth Blackwell, 🩺 the first woman to earn a medical degree in the U.S. in 1849 at Geneva Medical College, today @upstatemedical.bsky.social
011
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Science Magazine @science.org · 01/02/2026
In Science, researchers report the formation of platelet-derived integrin-and tetraspanin-enriched tethers (PITTs) in patients with severe infections. PITTs may contribute to blood clotting, immune dysregulation, and bleeding complications that characterize severe infections. scim.ag/4q3CJMP
scim.ag
Tethered platelets in severe infection
Platelet-derived structures in blood vessel walls increase inflammation and bleeding risk
0296
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Nonia Pariente @npariente.bsky.social · 28/01/2026
The names of 72 female scientists will be added to the Eiffel Tower, to accompany those of 72 male scientists that are already engraved there tinyurl.com/e2satnyp 👏👩‍🔬 🧪
View of the lower arch of the Eiffel Tower
18933
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Dimitri Drekonja, MD, MS @dimitridrekonja.bsky.social · 24/01/2026
Alex Pretti was a colleague at the VA. We hired him to recruit for our trial. He became an ICU nurse- I lover working with him. He was a good kind person who lived to help and these fuckers executed him. White. Hot. Rage.
13856005318628
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 17/01/2026
From @rollingstone.com HHS GAVE A $1.6 MILLION GRANT TO A CONTROVERSIAL VACCINE STUDY. THESE EMAILS SHOW HOW THAT HAPPENED www.rollingstone.com/politics/pol...
rollingstone.com
HHS Gave a $1.6 Million Grant to a Controversial Vaccine Study. These Emails Show How That Happened
Two Danish researchers faced accusations of “questionable research practices” as RFK Jr.’s top appointees made their study a “funding priority.”
010
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 14/01/2026
It was such a great privilege to join @angeladavismpr.bsky.social @mprnews.org this morning! Coinciding w/@americancancersoc.bsky.social reporting 5-year survival for all cancers now reaching 70%. The broadcast is available online now: www.mprnews.org/episode/2026... #cancerresearch #cancer
mprnews.org
How research has improved cancer treatments
A cancer diagnosis today can be much different than it used to be. MPR News host Angela Davis talks about improvements in cancer treatments — including better drugs, surgical advances, precision radia...
030
Reposted by Emil Lou, MD, PhD, FACP, FASCO
The Washington Post @washingtonpost.com · 14/01/2026
For the first time, the five-year survival rate for all cancers has reached 70 percent, according to a new report, a trend that reflects the effectiveness of early prevention and detection strategies, and advancements in treatment and care, experts say. wapo.st/45T6Zm3
910822
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 13/01/2026
I'm looking forward to joining @angeladavismpr.bsky.social and team @mprnews.org tomorrow Wednesday January 14, 2026 at 9:00 am to discuss "How research has improved cancer treatments". Join us! www.mprnews.org/episode/2026...
mprnews.org
How research has improved cancer treatments
A cancer diagnosis today can be much different than it used to be. Coming up at 9 a.m. on Wednesday, MPR News host Angela Davis talks about improvements in cancer treatments — including better drugs,...
030
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 11/01/2026
My Biochemistry-centric view on the excitement out of #GI26 as long (desperately)-awaited success in effective targeting of KRAS therapeutically has come into its own, but… www.linkedin.com/posts/emillo...
linkedin.com
#gi26 #biochemistry #oncology #cancerresearch #research #biochem #kras #coloncancer #colorectalcancer #pancreaticcancer | Emil Lou, M.D., Ph.D, FACP
A lot of excitement out of #GI26 as long (desperately)-awaited success in effective targeting of KRAS therapeutically has come into its own. Reports of early success in the form of promising efficacy ...
030
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 11/01/2026
#GI26 @ascocancer.bsky.social ushering in a Bronze Age of KRAS targeted therapy…next question is What Drug Class to Best Pair It With (that scientifically makes sense)? (!)
031
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 07/01/2026
Listening to The Beatles' classic "We Can Work It Out" while writing point-by-point Response to Reviewer 2 is even more inspiring than I imagined.
020
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 23/05/2025
Coverage from MDLinx about our recently presented and published #immunotherapy #clinicaltrial targeting the intracellular checkpoint #CISH - completed at the Masonic Cancer Center, University of Minnesota: www.mdlinx.com/article/insi...
mdlinx.com
Inside a lifesaving 'last resort' clinical trial—have we finally solved the problem of chemo-resistant colon cancer? | MDLinx
When Emma Dimery, 35, was told her stage IV colon cancer was terminal, she’d exhausted nearly every standard treatment option—surgery, multiple rounds of chemotherapy, radiation, and immunotherapy. No...
031
Reposted by Emil Lou, MD, PhD, FACP, FASCO
The New York Times @nytimes.com · 31/12/2025
Two New York Times journalists joined Miles Taylor, a YouTuber and transport enthusiast, on a daylong journey across New York City area buses and trains before sale of the MetroCard ends on December 31.
nyti.ms
To Say Goodbye to the MetroCard, We Spent a Day Riding Every Transit System That Uses It
Two Times journalists joined Miles Taylor, a YouTuber and transport enthusiast, on a daylong journey across New York City area buses and trains before sale of the card ends on Dec. 31.
513123
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 28/12/2025
www.medscape.com/viewarticle/...
medscape.com
CISH-Targeted TILs Show Promise in GI Cancer Trial
Professor David Kerr discusses a recent study that used gene-edited tumor-infiltrating lymphocytes to target CISH, a novel immune checkpoint inhibitor.
031
Reposted by Emil Lou, MD, PhD, FACP, FASCO
Science Magazine @science.org · 28/12/2025
An analysis of U.S. water quality data reveals that most toxic chemicals remain poorly characterized or undetected in routine monitoring. The findings in Science suggest that the true scale of chemical risk to biodiversity and ecosystems may be significantly underestimated. scim.ag/4alqHdl
scim.ag
Limitations of chemical monitoring hinder aquatic risk evaluations on the macroscale
Macroscale evaluations of chemical monitoring data require the integration of chemical, spatial, and temporal dimensions. Here, we linked 64 million US surface water monitoring records (1900 chemicals...
15319
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 27/12/2025
Has Your Scientific Work Been Cut? We Want to Hear. www.nytimes.com/2025/10/08/c...
nytimes.com
Has Your Scientific Work Been Cut? We Want to Hear.
010